Generic Drugmaker To High Court: Federal Circuit Patent Opinion Poses Risks
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals was wrong to reverse a Delaware federal judge’s finding of no induced infringement in a patent dispute involving a generic bioequivalent...To view the full article, register now.
Already a subscriber? Click here to view full article